JP2022551254A5 - - Google Patents

Info

Publication number
JP2022551254A5
JP2022551254A5 JP2022520234A JP2022520234A JP2022551254A5 JP 2022551254 A5 JP2022551254 A5 JP 2022551254A5 JP 2022520234 A JP2022520234 A JP 2022520234A JP 2022520234 A JP2022520234 A JP 2022520234A JP 2022551254 A5 JP2022551254 A5 JP 2022551254A5
Authority
JP
Japan
Prior art keywords
compound
salt according
following
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551254A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/059103 external-priority patent/WO2021064571A1/en
Publication of JP2022551254A publication Critical patent/JP2022551254A/ja
Publication of JP2022551254A5 publication Critical patent/JP2022551254A5/ja
Pending legal-status Critical Current

Links

JP2022520234A 2019-10-01 2020-09-29 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2022551254A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962908715P 2019-10-01 2019-10-01
US62/908,715 2019-10-01
US201962925300P 2019-10-24 2019-10-24
US62/925,300 2019-10-24
PCT/IB2020/059103 WO2021064571A1 (en) 2019-10-01 2020-09-29 N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2022551254A JP2022551254A (ja) 2022-12-08
JP2022551254A5 true JP2022551254A5 (cg-RX-API-DMAC7.html) 2023-10-10

Family

ID=72811913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520234A Pending JP2022551254A (ja) 2019-10-01 2020-09-29 ヒト免疫不全ウイルスの複製阻害剤

Country Status (4)

Country Link
US (1) US20220389007A1 (cg-RX-API-DMAC7.html)
EP (1) EP4038068A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022551254A (cg-RX-API-DMAC7.html)
WO (1) WO2021064571A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체

Similar Documents

Publication Publication Date Title
CN100396682C (zh) 用于制备喜树碱衍生物(cpt-11)以及相关化合物的中间体和方法
JP6392436B2 (ja) 置換された5−フルオロ−1h−ピラゾロピリジン類を製造するための方法
JP2022552156A5 (cg-RX-API-DMAC7.html)
CN113490668B (zh) 用于治疗与apj受体活性有关的疾病的化合物和组合物
JP7744955B2 (ja) 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
CN107709298A (zh) 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物
JP2023517043A5 (cg-RX-API-DMAC7.html)
AP805A (en) Process for substituted pyridines.
TW202233614A (zh) 作為激酶抑制劑之三唑并吡啶化合物
JPWO2016121777A1 (ja) ピラジンカルボキサミド化合物の製造方法及びその合成中間体
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
TWI884151B (zh) 製備4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氫嘧啶-6-基]甲基]-3-側氧-5,6,8,8a-四氫-1H-咪唑并[1,5-a]吡-2-基]-羧酸之替代方法
JP2025510230A (ja) Shp2阻害剤の調製プロセス
TW202229251A (zh) 乙醯胺基-苯基苯甲醯胺衍生物及其使用方法
EP4538259A1 (en) Processes for the preparation of deucravacitinib
WO2025245089A1 (en) Processes for preparing tetralin compounds
CN116745282A (zh) 抑制2-羟环烷-1-氨甲酰基衍生物的半乳糖凝集素-3
EP3560927A1 (en) Azepine derivative acting as 5-ht7 receptor modulator
JP2005535595A (ja) 4−ハロアルキルニコチン酸アミドの製造